Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

3 Jun 2017

Abstract excerpt

Abstract Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion–positive cancers. Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance. LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28578312
DOI: 10.1158/2159-8290.cd-17-0507

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsPMID 28578312Read ↗

Larotrectinib for the treatment of TRK fusion solid tumorsSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.Semantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Resistance Associated with Protein MutationSemantic proximity Read ↗

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinibSemantic proximity Read ↗

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.Semantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

Fast-TRKing Drug Development for Rare Molecular Targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.